FAPI Development2021-05-21T17:56:07+00:00

FAPI DEVELOPMENT

FAPI

SOFIE licensed a family of theranostic compounds that target the tumor stroma from the University of Heidelberg, the team that invented PSMA-617 (Novartis). The FAPI compounds inhibit the fibroblast activation protein, which is an important cancer target. Over 500 patients have been imaged to date with the diagnostic compound and initial therapeutic studies are underway. FAPI received the Product/Image/Publication of the Year Award at the Society for Nuclear Medicine and Molecular Imaging.

“FAPI is opening new doors in nuclear medicine, not only in imaging but also in theranostics.”

Dr. Frederick Giesel, M.D, M.B.A.
Universität Heidelberg · Nuclear Medicine

PUBLICATIONS

FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?

Katharina Dendl 1,2 Stefan A. Koerber 3,4,5 Clemens Kratochwil 1 Jens Cardinale 1,2 Rebecca Finck 1 Mardjan Dabir 2 Emil Novruzov 2Tadashi Watabe 6 Vasko Kramer 7,8 Peter L. Choyke 9 Uwe Haberkorn 1,10,11 and Frederik L. Giesel 1,2 Abstract:A fibroblast activation protein (FAP) [...]

November 2nd, 2021|Publications|

FAPI-74 PET/CT Using Either 18 F-AlF or Cold-Kit 68 Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients

Frederik L Giesel 1, Sebastian Adeberg 2 3 4 5, Mustafa Syed 2 4, Thomas Lindner 1, Luis David Jiménez-Franco 6, Eleni Mavriopoulou 1, Fabian Staudinger 1, Eric Tonndorf-Martini 2 4, Sebastian Regnery 2 4, Stefan Rieken 2 5 7, Rami El Shafie 2 5, Manuel Röhrich 1, Paul Flechsig 1, Andreas Kluge 6, Annette Altmann 1, Jürgen Debus 2 3 4 5, Uwe Haberkorn 8 9, Clemens Kratochwil 1 Abstract: 68Ga-fibroblast activation protein inhibitors (FAPIs) 2, 4, and 46 have already been proposed as promising PET tracers. However, the short half-life [...]

February 24th, 2021|Publications|

68 Ga-NOTA-FAPI-04 PET/CT in a patient with primary gastric diffuse large B cell lymphoma: comparisons with [ 18 F] FDG PET/CT

Guochang Wang # 1, Xiao Jin # 1, Hua Zhu 1, Shuailiang Wang 1, Jin Ding 1, Yan Zhang 1, Zhi Yang 2, Xuejuan Wang 3 Article available for purchase or with subscription. Affiliations: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian, Beijing, 100142, China. [...]

February 24th, 2021|Publications|

INTERESTED IN FAPI?

Guided by our Scientific Advisory Board, sanctioned peer-reviewed publications, and our own FAPI development plan, we remain committed to the process of making FAPI precursor material and radiolabeled compounds readily available.

HOSPITALS

Are you a hospital or clinic interested in participating in our clinical trial? Following the filing of its IND, we will be launching a FAPI-based clinical trial. We expect to collaborate to achieve the required designed endpoints.

RESEARCHERS

Are you an academic researcher interested in evaluating the FAPI compounds within the preclinical and clinical space for both mainstream and unique applications? Our partners at ABX will have you up and running quickly.

PHARMACEUTICAL COMPANIES

Are you a pharmaceutical company or distribution network interested obtaining FAPI for your projects and patients? We are eager to learn more about how our compounds can facilitate your needs. Contact us today.

COMMERCIAL PARTNERS

Trasis

SOFIE has selected an automated radiosynthesizer for standardized production of its Ga-68 FAPI and F-18 FAPI. This will facilitate production at SOFIE’s facilities for supply to its clinical trial sites.

Covance

US-based FAPI-46 and FAPI-74 Tox studies have been completed by Covance at its Indianapolis facility.

abx

ABX is SOFIE’s partner of choice for our FAPI precursor production. ABX has successfully completed the manufacture and shipment of the first stocks of FAPI precursor material, enabling our distribution of precursor and reference standards under MTAs to multiple approved users in the US and EU.

FAPI is not currently approved for general clinical use and should therefore be utilized in accordance with established regulatory guidelines in each jurisdiction.

SCIENTIFIC ADVISORY BOARD

Uwe Haberkorn, MD, PhD

Uwe Haberkorn, MD, PhD

  • Inventor of the FAPI theranostic family
  • Chair of the Department of Nuclear Medicine at the University of Heidelberg
  • Head of the Clinical Cooperation Unit of Nuclear Medicine at the DKFZ
Stefano Fanti, MD

Stefano Fanti, MD

  • Chairman of FAPI Scientific Advisory Board
  • Head of Nuclear Medicine, University of Bologna
Frederick Giesel MD, MBA

 Frederick Giesel, MD, MBA

  • Vice Chair of Nuclear Medicine, Department of Nuclear Medicine, University Hospital Heidelberg
  • Full Professor at Osaka University, Osaka Japan and expert in the field oncological theranostics
Clemens Kratochwil, MD

 Clemens Kratochwil, MD

  • Attending and Director, Therapy Unit, Department of Nuclear Medicine at the University of Heidelberg
Jens Siveke, MD

 Jens Siveke, MD

  • Head of the Division of Solid Tumor Translational Oncology (DKFZ/DKTK partner site Essen)
  • Full Professor in the Department of Medical Oncology at the West German Cancer Center, University Hospital Essen
Johannes Czernin, MD

Johannes Czernin, MD

  • Nuclear Medicine and Internal Medicine
  • Chief, Ahmanson Translational Imaging Division at UCLA
Ken Herrmann, MD, MBA

Ken Herrmann, MD, MBA

  • Chair of Nuclear Medicine at the University of Duisburg-Essen

CONTACT US

Are you a pharmaceutical company or distribution network interested obtaining FAPI for your projects and patients? We are eager to learn more about how our compounds can facilitate your needs.

Go to Top